Highlights

  • Alterity Therapeutics (ASX:ATH) has raised A$4.2 million through the issue of 8.4 million new shares following an underwritten Options shortfall.
  • The funding provides additional Working Capital as the company prepares for a pivotal Phase 3 program evaluating ATH434 in multiple system atrophy.
  • The Underwriting carries a 7% fee, meaning net proceeds will be below the A$4.2 million headline amount.
  • Phase 3 commencement, cash runway and future funding requirements remain the main areas to monitor.

Alterity Therapeutics (ASX:ATH) has strengthened its near-term funding position after an underwriting arrangement converted an expiring options shortfall into A$4.2 million of gross proceeds.

The capital arrives as the clinical-stage biotechnology company prepares to move its lead neurological candidate, ATH434, toward a pivotal Phase 3 program in multiple system atrophy. While the additional funding supports working capital, it also increases the number of shares on issue and does not remove the larger funding demands associated with late-stage clinical development.

What was announced, and when

In late August 2026, Alterity Therapeutics (ASX:ATH) announced the issue of 8.4 million fully paid ordinary shares at A$0.50 each, raising A$4.2 million.

The shares were issued to MST Financial Services Pty Ltd and participating sub-underwriters under an underwriting agreement established in late August 2026.

That agreement covered Alterity’s listed ATHO options, which carried an exercise price of A$0.50 and reached expiry at the end of August.

The arrangement effectively ensured that any shortfall in option exercises could still be converted into new Equity capital for the company.

The stated purpose of the proceeds is additional working capital.

What Alterity is developing

Alterity Therapeutics (ASX:ATH), formerly known as Prana Biotechnology Limited, is focused on treatments for neurodegenerative diseases.

Its lead development candidate is ATH434, which is being developed for multiple system atrophy, or MSA.

MSA is a rare and progressive neurodegenerative disorder characterised by Parkinsonian symptoms and dysfunction of the autonomic nervous system.

Alterity has completed Phase 2 clinical work across two studies.

The company has described its randomised controlled ATH434-201 study as demonstrating clinically meaningful efficacy, while its open-label ATH434-202 study in more advanced patients has also produced positive data.

The next major step is a pivotal Phase 3 program.

During 2026, Alterity announced that it had reached agreement with the US Food and Drug Administration on the Phase 3 development pathway for ATH434.

That regulatory engagement helps define the proposed study design and registrational route.

However, agreement on a Phase 3 program is not the same as commencement of the trial, and the existing Phase 2 results do not constitute regulatory approval.

How the underwriting works

An options underwriting arrangement is different from a conventional placement.

If optionholders exercise their securities, the company receives the exercise proceeds directly from them.

If some options are not exercised, the underwriter agrees to subscribe for the shortfall, subject to the terms of the underwriting agreement.

In Alterity’s case, 8.4 million shares were issued at A$0.50 each to MST Financial and its sub-underwriters, producing the A$4.2 million gross funding amount.

That indicates the underwritten shortfall was taken up through the underwriting structure.

The available disclosures do not establish how many additional ATHO options may have been exercised separately by existing holders.

The headline amount is not the net amount

The A$4.2 million figure represents gross proceeds.

MST Financial is entitled to an underwriting fee equal to 7% of gross proceeds.

On A$4.2 million, that equates to approximately A$294,000 before considering any other associated expenses.

As a result, the amount available to Alterity for working capital will be lower than the headline figure.

The company relied on an applicable ASX Listing Rule exception for the issue, meaning separate Shareholder approval was not required for the underwritten shares.

Dilution remains part of the trade-off

The funding provides additional liquidity, but it also increases Alterity’s Issued Capital by 8.4 million shares.

For a clinical-stage biotechnology company, this is a familiar trade-off.

Late-stage studies can require substantial expenditure across clinical sites, manufacturing, monitoring, regulatory activities and data management.

Equity funding can extend the development runway without adding debt, but repeated issuance spreads ownership across a larger number of shares.

Alterity has already used several funding sources to support development.

The company completed a A$20 million Placement in 2025 and also received an R&D tax incentive of approximately A$3.98 million during 2026.

The latest underwriting therefore forms part of a broader pattern of capital support as ATH434 moves toward a more expensive stage of clinical development.

Phase 3 remains the key clinical milestone

The funding announcement does not change the central Investment question around Alterity Therapeutics (ASX:ATH): whether ATH434 can successfully progress through pivotal clinical development.

The company has established the regulatory framework for a Phase 3 program, but the next meaningful operational milestone is confirmation that the study has actually commenced.

A pivotal trial represents a significantly larger undertaking than Phase 2.

It requires sufficient capital not only to start recruitment but also to sustain enrolment, treatment, monitoring and follow-up through to data readout.

That makes funding visibility especially important.

The A$4.2 million underwriting strengthens the near-term position, but it should not automatically be assumed to cover the full cost of the planned Phase 3 program.

Funding risk remains

Alterity remains a clinical-stage biotechnology company without meaningful product revenue.

Its ability to progress ATH434 therefore continues to depend on existing cash, tax incentives, capital raisings and potentially future partnering arrangements.

The current funding provides additional working capital but does not eliminate the possibility of further financing.

Potential future options include another institutional raising, additional non-dilutive support or a Partnership that contributes capital toward clinical development.

Each carries different implications for shareholders.

Additional equity could create further dilution, while a partnership may involve sharing future commercial economics.

What to watch

The first area to monitor is confirmation that the pivotal Phase 3 study of ATH434 has formally commenced.

The second is the company’s latest cash position and quarterly cash expenditure, which will provide a clearer indication of the runway available after the underwriting proceeds.

The third is the scale of funding ultimately required to carry the Phase 3 program through its major clinical milestones.

A fourth Factor is partnering activity.

If Alterity can secure a development or commercial partner for ATH434, that could change the funding profile materially.

For Alterity Therapeutics (ASX:ATH), the A$4.2 million underwriting adds useful capital ahead of a major clinical-development phase. The more important question now is how far that funding extends the runway and whether the company can move ATH434 from Phase 3 planning into active pivotal development.